54 -12 (86) 2025 - Abdullaeva U.K., Mirzaev S.Kh. - THE ROLE OF INTESTINAL MICROBIOTA IN THE COURSE OF AUTOIMMUNE LIVER DISEASES

THE ROLE OF INTESTINAL MICROBIOTA IN THE COURSE OF AUTOIMMUNE LIVER DISEASES

Abdullaeva U.K. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Recent studies have identified the critical role of microbiota in the pathophysiology of autoimmune liver diseases (AILDs), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). Metagenomic studies reveal significant decrease of gut bacterial diversity in AILDs. Although profiles of metagenomic vary widely, Veillonella is commonly enriched in AIH, PBC, and PSC. Apart from gut microbiome, the oral and bile microbiome seem to be associated with these diseases as well. The functional analysis of metagenomics suggests that metabolic pathways changed in the gut microbiome of the patients. Microbial metabolites, including shortchain fatty acids (SCFAs) and microbial bile acid metabolites, have been shown to modulate innate immunity, adaptive immunity, and inflammation. Taken together, the evidence of host–microbiome interactions and in-depth mechanistic studies needs further accumulation, which will offer more possibilities to clarify the mechanisms of AILDs and provide potential molecular targets for the prevention and treatment in the future.

Keywords: autoimmune liver diseases, microbiome, metagenomic, metabolomic, bile acids

First page

301

Last page

310

For citation:Abdullaeva U.K., Mirzaev S.Kh. - THE ROLE OF INTESTINAL MICROBIOTA IN THE COURSE OF AUTOIMMUNE LIVER DISEASES//New Day in Medicine 12(86)2025 301-310 https://newdayworldmedicine.com/en/new_day_medicine/12-86-2025

List of References

1. Allegretti J. R., Kassam Z., Carrellas M., Mullish B. H., Marchesi J. R., Pechlivanis A., et al. (2019). Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am. J. Gastroenterol. 2019;114:1071-1079.
2. Bergot A. S., Giri R., and Thomas R. (2019). The microbiome and rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 2019;33:101497.
3. Biewenga M., Farina Sarasqueta A., Tushuizen M. E., de Jonge-Muller E. S. M., van Hoek B., and Trouw L. A. (2020). The role of complement activation in autoimmune liver disease. Autoimmun. Rev. 2020;19:102534.
4. Chen W., Wei Y., Xiong A., Li, Y., Guan, H., Wang, Q., et al. (2020). Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis. Clin. Rev. Allergy Immunol. 2020;58:25-38.
5. Cortez R.V., Moreira L.N., Padilha, M., Bibas M.D., Toma R.K., Porta G., et al. (2020). Gut microbiome of children and adolescents with primary sclerosing cholangitis in association with ulcerative colitis. Front. Immunol. 2020;11:598152.
6. Dekaboruah, E., Suryavanshi, M. V., Chettri, D., and Verma, A. K. (2020). Human microbiome: an academic update on human body site specific surveillance and its possible role. Arch. Microbiol. 202, 2147–2167.
7. Elmaghrawy, K., Hussey, S., and Moran, G. P. (2020). The oral microbiome in pediatric IBD: a source of pathobionts or biomarkers? Front Pediatr. 8:620254.
8. Elsherbiny, N. M., Rammadan, M., Hassan, E. A., Ali, M. E., El-Rehim, A. S. A., Abbas, W. A., et al. (2020). Autoimmune hepatitis: shifts in gut microbiota and metabolic pathways among egyptian patients. Microorganisms 8:1011.
9. Franzosa, E. A., Sirota-Madi, A., Avila-Pacheco, J., Fornelos, N., Haiser, H. J., Reinker, S., et al. (2019). Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat. Microbiol. 4, 293–305.
10. Furukawa, M., Moriya, K., Nakayama, J., Inoue, T., Momoda, R., Kawaratani, H., et al. (2020). Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. Hepatol. Res. 50, 840–852.

    file

    download